Publication Name	World Journal of Hepatology
Manuscript ID	16713
Country	Brazil

Received	2015-01-28 10:47
Peer-Review Started	2015-01-28 19:48
To Make the First Decision	2015-02-07 14:45
Return for Revision	2015-02-11 19:08
Revised	2015-02-21 08:34
Second Decision	2015-03-16 17:50
Accepted by Journal Editor-in-Chief	2015-03-16 23:09
Accepted by Executive Editor-in-Chief	2015-04-02 16:23
Articles in Press	2015-04-02 16:23
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-05-02 15:55
Publish the Manuscript Online	2015-05-19 17:28

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Editorial
Article Title	Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease
Manuscript Source	Invited Manuscript
All Author List	Vanessa Souza-Mello
Funding Agency and Grant Number
Corresponding Author	Vanessa Souza-Mello, RD, PhD, Biomedical Centre, Institute of Biology, Department of Anatomy, State University of Rio de Janeiro, Av. 28 de Setembro 87, Fundos, Vila Isabel, Rio de Janeiro 20551-030, Brazil. souzamello.uerj@gmail.com
Key Words	Peroxisome proliferator-activated receptors; Non-alcoholic fatty liver disease; Obesity; Treatment; Insulin resistance; Beta-oxidation; Lipogenesis
Core Tip	Multiple pathways disrupted in obesity and non-alcoholic fatty liver disease (NAFLD) are regulated by genes encoded by peroxisome proliferator-activated receptors (PPARs). Thus, PPARs emerged as potential targets to alleviate NAFLD. The use of PPAR-alpha agonist yields increased mitochondrial beta-oxidation coupled with reduced lipogenesis. Both of them are essential to tackle insulin resistance and hepatic steatosis. PPAR-beta/delta agonist is still not available as a medicine, but PPAR-beta/delta agonist elicited expressive reduction in hepatic glucose production in murine models. PPAR-gamma agonist is extensively used, and beneficial effects come from partial activation as total PPAR-gamma activation leads to hepatic lipogenesis, being harmful to the liver.
Publish Date	2015-05-19 17:28
Citation	Souza-Mello V. Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease. World J Hepatol 2015; 7(8): 1012-1019
URL	http://www.wjgnet.com/1948-5182/full/v7/i8/1012.htm
DOI	http://dx.doi.org/10.4254/wjh.v7.i8.1012

Full Article (PDF)	WJH-7-1012.pdf
Full Article (Word)	WJH-7-1012.doc
Manuscript File	16713-Review.doc
Answering Reviewers	16713-Answering reviewers.pdf
Conflict-of-Interest Disclosure Form	16713-Conflict-of-interest statement.pdf
Copyright License Agreement	16713-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	16713-Language certificate.pdf
Journal Editor-in-Chief Review Report	16713-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	16713-Scientific misconduct check.pdf
Scientific Editor Work List	16713-Scientific editor work list.pdf